ZOGENIX, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2011-12-21: Form 8-K; Period of report 2011-12-20; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; Details 1.01.
- 2011-11-10: Form 8-K; Period of report 2011-11-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2011-10-13: Form 8-K/A; Period of report 2011-05-24; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2011-08-17: Form 8-K; Period of report 2011-08-17; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2011-12-21 | 8-K | 2011-12-20 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. 1.02 The Company and Astellas agreed to terminate the Agreement effective as of March 31, 2012 pursuant to the Amendment. | d274449d8k.htm |
| 2011-11-10 | 8-K | 2011-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2011, Zogenix, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2011. | d254255d8k.htm |
| 2011-10-13 | 8-K/A | 2011-05-24 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 This Current Report on Form 8-K/A is being filed as an amendment to the Current Report on Form 8-K filed on May 25, 2011 by Zogenix, Inc. (the “Company”) in order to update information disclosed under “Item 5.07 Submission of Matters to a Vote of Security Holders” regarding the results of voting at the Company’s annual meeting of stockholders held on May 24, 2011 (the “2011 Annual Meeting”). | d242964d8ka.htm |
| 2011-08-17 | 8-K | 2011-08-17 | 8.01 Other Events | 8.01 On August 17, 2011, Zogenix, Inc. (the “Company” or “Zogenix”) announced positive top-line results from its pivotal Phase 3 efficacy trial (Study 801) of Zohydro™ (hydrocodone bitartrate) extended-release capsules. | d8k.htm |
| 2011-08-10 | 8-K | 2011-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2011, Zogenix, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2011. | d8k.htm |
| 2011-07-18 | 8-K | 2011-07-18 | 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 3.02 On July 18, 2011, Zogenix, Inc. (“Zogenix”) and Cowen Healthcare Royalty Partners II, L.P. (“Cowen Royalty”) closed the stock and warrant issuance previously announced in connection with the Cowen Royalty royalty financing. 8.01 A copy of the press release, dated July 18, 2011, is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. | d8k.htm |
| 2011-07-12 | 8-K | 2011-07-11 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On July 11, 2011, Zogenix, Inc., a Delaware corporation (“Zogenix”), entered into a Development and License Agreement (the “License Agreement”) with Durect Corporation, a corporation organized under the laws of the State of Delaware (“Durect”). 8.01 A copy of the press release, dated July 12, 2011, is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. | d8k.htm |
| 2011-07-01 | 8-K | 2011-06-30 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 On June 30, 2011 (“Execution Date”), Zogenix, Inc., a Delaware corporation (“Zogenix”), entered into a Financing Agreement (the “Financing Agreement”) with Cowen Healthcare Royalty Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“CHRP”). 1.02 On June 30, 2011, and in connection with entering into the Financing Agreement and the amendment to the Oxford Loan Agreement, Zogenix paid off all remaining outstanding amounts under its Master Loan and Security Agreement dated as of March 5, 2007 (as amended and supplemented) with General Electric Capital Corporation (the “GE Loan Agreement”). 2.03 (a) The information set forth under Item 1.01 of this Current Report on Form 8-K regarding the Financing Agreement is hereby incorporated by reference. 3.02 The information set forth under Item 1.01 of this Current Report on Form 8-K regarding the Purchase Agreement is hereby incorporated by reference. 8.01 A copy of the press release, dated June 30, 2011, is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. | d8k.htm |
| 2011-05-25 | 8-K | 2011-05-24 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The Company held its annual meeting of stockholders on May 24, 2011. | d8k.htm |
| 2011-05-16 | 8-K | 2011-05-16 | 2.02 Results of Operations and Financial Condition | 2.02 On May 16, 2011, Zogenix, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2011. | d8k.htm |
| 2011-04-28 | 8-K | 2011-04-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 27, 2011, Ken Haas notified the board of directors of Zogenix, Inc. that he will not be standing for re-election for the coming year. | d8k.htm |
| 2011-04-15 | 8-K | 2011-04-13 | 8.01 Other Events | 8.01 On April 13, 2011, Zogenix, Inc. (the “Company” or “Zogenix”), at the 63rd Annual Meeting of the American Academy of Neurology in Honolulu, Hawaii, presented clinical data from its Phase 4 open-label, multicenter study of SUMAVEL® DosePro ® (sumatriptan injection) Needle-free Delivery System. | d8k.htm |
| 2011-03-16 | 8-K | 2011-03-16 | 8.01 Other Events | 8.01 On March 16, 2011, Zogenix, Inc. (the “Company” or “Zogenix”) announced that a recently issued patent (U.S. patent number 7,776,007) which covers the Company’s branded migraine treatment, SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System, has been listed in the U.S. Food and Drug Administration Orange Book. | d8k.htm |
| 2011-03-04 | 8-K | 2011-03-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | d8k.htm | |
| 2011-03-03 | 8-K | 2011-03-03 | 2.02 Results of Operations and Financial Condition | 2.02 On March 3, 2011, Zogenix, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full-year ended December 31, 2010. | d8k.htm |
| 2011-01-10 | 8-K | 2011-01-10 | 7.01 Regulation FD Disclosure | 7.01 During the week of January 10, 2011, representatives of Zogenix, Inc. will be attending meetings with investors, analysts and others in connection with the JP Morgan Healthcare conference in San Francisco, California. | d8k.htm |